Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
- PMID: 12480690
- DOI: 10.1182/blood-2002-10-3146
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
Erratum in
-
Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003;101(9):3606-3614.Blood. 2024 Jul 11;144(2):239. doi: 10.1182/blood.2024025274. Blood. 2024. PMID: 38990539 No abstract available.
Abstract
Our previous study demonstrated that 2-methoxyestradiol (2ME2), an estrogen derivative, induces apoptosis in multiple myeloma (MM) cells; however, the related transcriptional events are unclear. In the present study, we used oligonucleotide microarrays to identify genes altered during 2ME2-induced apoptosis in MM cells. 2ME2 triggers an early transient induction of genes known to trigger cell death and repression of growth/survival-related genes. Many genes regulating cell defense/repair machinery also were transiently induced. Since 2ME2 also induces apoptosis in MM cells resistant to conventional therapies such as dexamethasone (Dex), we compared the gene profiles of 2ME2-treated and Dex-resistant MM cells. Our results suggest that 2ME2 overcomes Dex resistance by modulating genes that confer chemoresistance in MM cells. Microarray results were confirmed by Northern and Western blot analyses. A comparative analysis of selected genes from freshly isolated MM patient cells and 2ME2-treated MM.1S MM cells further provides an in vivo relevance of our in vitro studies. Collectively, these findings suggest genetic events mediating anti-MM activity of 2ME2, as well as mechanisms whereby 2ME2 overcomes Dex resistance in MM cells. These studies may therefore allow improved therapeutic use of 2ME2, based upon targeting genes that regulate MM cell growth and survival.
Similar articles
-
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.Oncogene. 2002 Feb 21;21(9):1346-58. doi: 10.1038/sj.onc.1205205. Oncogene. 2002. PMID: 11857078
-
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.Apoptosis. 2004 Mar;9(2):149-55. doi: 10.1023/B:APPT.0000018797.66067.6c. Apoptosis. 2004. PMID: 15004512
-
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Blood. 2002 Sep 15;100(6):2187-94. doi: 10.1182/blood-2002-02-0376. Blood. 2002. PMID: 12200384
-
New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent.Curr Opin Oncol. 2003 Nov;15(6):425-30. doi: 10.1097/00001622-200311000-00004. Curr Opin Oncol. 2003. PMID: 14624224 Review.
-
Mechanism of action of 2-methoxyestradiol: new developments.Drug Resist Updat. 2003 Dec;6(6):355-61. doi: 10.1016/j.drup.2003.10.001. Drug Resist Updat. 2003. PMID: 14744499 Review.
Cited by
-
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.Am J Hematol. 2013 Apr;88(4):265-72. doi: 10.1002/ajh.23387. Epub 2013 Mar 8. Am J Hematol. 2013. PMID: 23475625 Free PMC article.
-
Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.PLoS One. 2014 Mar 21;9(3):e92478. doi: 10.1371/journal.pone.0092478. eCollection 2014. PLoS One. 2014. Retraction in: PLoS One. 2021 Jun 10;16(6):e0253350. doi: 10.1371/journal.pone.0253350. PMID: 24658061 Free PMC article. Retracted.
-
2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats.Vascul Pharmacol. 2009 Aug-Sep;51(2-3):190-7. doi: 10.1016/j.vph.2009.06.002. Epub 2009 Jun 21. Vascul Pharmacol. 2009. PMID: 19540933 Free PMC article.
-
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.Expert Rev Mol Diagn. 2010 May;10(4):465-80. doi: 10.1586/erm.10.31. Expert Rev Mol Diagn. 2010. PMID: 20465501 Free PMC article. Review.
-
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. doi: 10.1073/pnas.2536759100. Epub 2003 Dec 26. Proc Natl Acad Sci U S A. 2004. PMID: 14695887 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical